ResMed
950 hedge funds and large institutions have $25.1B invested in ResMed in 2025 Q3 according to their latest regulatory filings, with 119 funds opening new positions, 345 increasing their positions, 324 reducing their positions, and 75 closing their positions.
59% more first-time investments, than exits
New positions opened: 119 | Existing positions closed: 75
5% more capital invested
Capital invested by funds: $23.9B → $25.1B (+$1.22B)
3% more funds holding
Funds holding: 920 → 950 (+30)
6% more repeat investments, than reductions
Existing positions increased: 345 | Existing positions reduced: 324
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.5% less ownership
Funds ownership: 63.29% → 62.79% (-0.5%)
76% less call options, than puts
Call options by funds: $95.5M | Put options by funds: $400M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$146M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$117M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$92.8M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$90M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$81.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$135M |
| 2 |
Morgan Stanley
New York
|
-$94.8M |
| 3 |
Squarepoint
New York
|
-$81.1M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$78.7M |
| 5 |
LCP
LGT Capital Partners
Pfaeffikon,
Switzerland
|
-$73.1M |
RMD Hedge Fund Activity: Q3 2025 in Review
950 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q3 2025, worth a combined $25.1B — up 5.1% from $23.9B a quarter earlier.
Buyers outnumbered sellers: 119 funds opened new RMD positions and 75 closed out — a net gain of 44 holders — while 345 added to existing stakes and 324 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $146M. The largest seller was Bank of New York Mellon, cutting an estimated $135M.
- 950 institutional investors held ResMed (RMD) as of Q3 2025, up from 920 in Q2 2025.
- Funds reported $25.1B of ResMed stock for Q3 2025, up 5.1% quarter-over-quarter.
- 119 funds opened new ResMed positions in Q3 2025 and 75 closed out, a net change of +44 holders.
- The largest ResMed buyer in Q3 2025 was Fidelity Investments, an estimated $146M added.
- The largest ResMed seller in Q3 2025 was Bank of New York Mellon, an estimated $135M sold.
Based on aggregated 13F filings for Q3 2025.